A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy

Karissa L. Gable, Stojan Peric, Michael W. Lutz, Ivo Bozovic, Milutin Petrovic, Aleksandar Stojanov, Ivana Basta, Jeffrey A. Allen

Research output: Contribution to journalArticlepeer-review


BACKGROUND AND AIMS: Fatigue is a common but poorly understood complaint in patients with immune-mediated polyneuropathies. We sought to evaluate changes in fatigue over 1 year in a cohort of chronic inflammatory demyelinating polyneuropathy (CIDP) patients and to correlate changes in fatigue with changes in disability and quality of life. Investigation into other factors that may contribute to fatigue with a particular interest in the role other chronic disease states may play was also performed.

METHODS: Fifty patients with CIDP who satisfied the 2010 EFNS/PNS diagnostic criteria were followed over the period of 1 year at three tertiary care centers in Serbia. Assessments of disability, quality of life, and patient perception of change and fatigue were collected at two time points 12 months apart. Comorbidities, treatment regimens, and sedating medication use was collected.

RESULTS: Disability, quality of life, and patient perception of change showed statistically significant correlations with change in fatigue (p < .01). Increased levels of fatigue were noted in patients who used sedating medications (p = .05) and who had a comorbid chronic medical condition (p = .01).

INTERPRETATION: Worsening fatigue correlates over time with increased disability and worse quality of life. Fatigue is not specific to CIDP, but is common in many chronic medical conditions and with the use of sedating medications. Our findings support the importance of identifying and supportively managing fatigue in patients with CIDP, but cautions against considering fatigue as a CIDP diagnostic symptom or using fatigue to justify immunotherapy utilization.

Original languageEnglish (US)
Article numbere2712
JournalBrain and Behavior
Issue number8
StatePublished - Aug 2022

Bibliographical note

Funding Information:
K. G. was a consultant for Apellis and Medscape. J. A. is a consultant for Argenx, alexion, annexon, Akcea, CSL behring, Johnson & Johnson, Grifols, Sanofi, Takeda. S. P. reports the following: he has received lecture honoraria from Pfizer, Viatris, Teva Actavis, Berlin Chemie Menarini, Mylan, Worwag, Adoc and Salveo; research grants from Kedrion, Octapharma and Argenx; consultant fees from Argenx, Mylan and Roche; and travel grants from Octapharma, Kedrion, Teva Actavis, Sanofi Genzyme, Pfizer, Roche, Adoc and Berlin Chemie Menarini. The remaining authors have no disclosures to report.

Publisher Copyright:
© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.


  • chronic inflammatory demyelinating polyneuropathy
  • fatigue
  • quality of life
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/complications
  • Polyneuropathies
  • Humans
  • Quality of Life
  • Fatigue/diagnosis
  • Chronic Disease

PubMed: MeSH publication types

  • Journal Article


Dive into the research topics of 'A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy'. Together they form a unique fingerprint.

Cite this